12:00 AM
 | 
Mar 04, 2013
 |  BioCentury  |  Emerging Company Profile

Vedantra: Boosting T cell responses

Vedantra developing nanoparticle-based vaccines for malaria, HPV

Vedantra Pharmaceuticals Inc. is developing nanoparticle vaccines that are designed to generate a more potent antibody and T cell response than traditional subunit vaccines. By delivering antigens and immunostimulatory adjuvants in multilayer lipid vesicles, the technology mimics the pathogen-associated molecular patterns necessary for a robust immune response.

Subunit vaccines are typically a mixture of one or more antigens from a target pathogen plus an adjuvant. They are effective at triggering an antibody response but often elicit poor or even no T cell responses. That is a problem because many viral diseases are thought to require a highly potent T cell response in addition to an antibody response to control and eradicate infection.

Vedantra has sought to solve that problem by developing vaccines based on a nanoparticle technology called inter-bilayer cross-linked multilamellar vesicles (ICMVs), which the company licensed from the lab of Darrell Irvine, professor of materials science and engineering and biological engineering at the Massachusetts Institute of Technology.

ICMVs are multilayered lipid vesicles designed to display antigens and immunostimulatory molecules in a way that mimics the molecular patterns infectious...

Read the full 881 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >